eFFECTOR Therapeutics (EFTR) Projected to Post Quarterly Earnings on Tuesday

eFFECTOR Therapeutics (NASDAQ:EFTR) is expected to be posting its quarterly earnings results on Tuesday, January 21st. Analysts expect eFFECTOR Therapeutics to post earnings of ($2.02) per share for the quarter.

eFFECTOR Therapeutics Stock Performance

EFTR opened at $0.00 on Friday. eFFECTOR Therapeutics has a 1 year low of $0.00 and a 1 year high of $17.75.

eFFECTOR Therapeutics Company Profile

eFFECTOR Therapeutics, Inc, a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer.